Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas.

Current problems in cancer - 1 Apr 2025

Murugan Avaniyapuram Kannan, Kannan Siddarth, Alzahrani Ali S

Abstract excerpt

Programmed cell death protein 1 (PDCD1) and cluster of differentiation 274 (CD274) expression is implicated in escaping tumors from immune surveillance. Immune checkpoint inhibitors show promise in cancer therapy, yet their efficacy in glioblastomas, particularly with IDH1 mutations, remains unclear. This study analyzed two independent NGS datasets (n = 577 and n = 153) from TCGA to investigate the expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Glioblastoma

Share to Immune Checkpoint Inhibitors

Share to Isocitrate Dehydrogenase

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 39864140
DOI: 10.1016/j.currproblcancer.2025.101182

Genes

IDH1
CD274
PDCD1
ITGB2
MUC16
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas.PMID 39864140Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

The immune regulation of BCL3 in glioblastoma with mutated IDH1.Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype.Semantic proximity Read ↗

Molecular profiling of CNS tumors for the treatment and management of disease.Semantic proximity Read ↗

Landscape of Genomic Alterations inIDHWild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic FactorSemantic proximity Read ↗

Updates in IDH-Wildtype Glioblastoma.Semantic proximity Read ↗

Integrated pathway analysis identifies prognostically relevant subtypes of glioblastoma characterized by abnormalities in multi-omics.Semantic proximity Read ↗

Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.Semantic proximity Read ↗

A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas DatasetSemantic proximity Read ↗

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risksSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.